|
Video: What is a Stock Split?
|
|
Achilles Therapeutics is a clinical stage immuno-oncology biopharmaceutical company developing T cell therapies to treat multiple types of solid tumors. Co.'s bioinformatic platform called PELEUS identifies mutations formed early in the development of a cancer that give rise to antigens. Co.'s manufacturing process, VELOS, uses the patient's T cells and blood-derived dendritic cells to create a Clonal Neoantigen Targeting T cell therapy that targets clonal neoantigens to eradicate the tumor. Co. also uses its Material Acquisition Platform network, which consists of a network of medical facilities, to collect tissue samples from other tumor types such as head and neck squamous cell carcinoma. According to our Achilles Therapeutics PLC stock split history records, Achilles Therapeutics PLC has had 0 splits. | |
|
Achilles Therapeutics PLC (ACHL) has 0 splits in our Achilles Therapeutics PLC stock split history database.
Looking at the Achilles Therapeutics PLC stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Achilles Therapeutics PLC shares, starting with a $10,000 purchase of ACHL, presented on a split-history-adjusted basis factoring in the complete Achilles Therapeutics PLC stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$16.00 |
|
End price/share: |
$0.76 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.25% |
|
Average Annual Total Return: |
-62.92% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$475.04 |
|
Years: |
3.07 |
|
|
|
|
|